Jennifer Schmidt

Jennifer Warner-Schmidt, PhD, is the Director of Preclinical Research and Development at Transcend Therapeutics, a company focused on the discovery, development and delivery of next-generation psychoactive medications for the treatment of neuropsychiatric diseases with an emphasis on developing medicines that are accessible to the tens of millions of patients already taking psychotropic medication.Dr. Warner-Schmidt received her BS in Systems Neuroscience from The Massachusetts Institute of Technology and her PhD in Neuroscience from Yale University in the laboratory of Prof. Ronald Duman where she studied the role of neurotrophins in the molecular, cellular and behavioral responses to antidepressants.Her postdoctoral work continued to investigate underlying psychopathology and antidepressant responses at the Rockefeller University with Dr. Paul Greengard. She explored the involvement of p11, a serotonin receptor binding protein, in preclinical studies of depression and antidepressant activity. Dr. Warner-Schmidt then founded NeuroJenic Consulting, LLC, to offer preclinical strategic and writing services to laboratories in academia and industry and has been working with biotech companies for the past 6 years, most recently as the Director of R&D at Magnolia Neurosciences.